63.4

Elena Diez‐Cecilia

University Health Network, Krembil Research Institute

Elena Diez-Cecilia has made significant contributions to the understanding of Alzheimer's disease, proposing a dual-action therapeutic platform that targets both immunopathic and proteopathic mechanisms. By inhibiting indoleamine 2,3-dioxygenase-mediated tryptophan metabolism and β-amyloid aggregation, their work suggests that AD may be an autoimmune disorder modulated by endogenous tryptophan metabolites. Additionally, research on artificial intelligence for COVID-19 drug discovery and vaccine development highlights the potential of AI in accelerating pandemic response efforts. Diez-Cecilia's findings also reveal the efficacy of novel compounds against protein misfolding and oligomerization of beta-amyloid, as well as their application as kinase inhibitors, with implications for various diseases beyond AD.

Commercial signal 63.3
Scientific signal 65.3
Social signal 62.3
Papers 11
3 Patent-to-paper cites
351 Paper cites

scientifiq.ai is an experimental platform. The platform relies on open source data and it may contain errors. Its primary goal is to advance scientific research on innovation.